Florida Cancer Specialists & Research Institute Welcomes Board-certified Hematologist & Medical Oncologist Daniel Ezekwudo, MD, PhD To Charlotte County

FORT MYERS, Fla., Oct. 1, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) has expanded its team of clinical experts in Charlotte County, with the addition of board-certified hematologist and medical oncologist Daniel Ezekwudo, MD, PhD. He is providing personalized care for all forms of cancer, with a special focus on thoracic, gastrointestinal, genitourinary, and breast cancers, at the FCS North Port Cancer Center at 1390, Grand Venture Dr., North Port, FL 34286 and the FCS Port Charlotte clinic at 22395 Edgewater Dr., Port Charlotte, FL, 33980.

"FCS is delighted to welcome Dr. Ezekwudo to our statewide practice," said David Wenk, MD, FCS assistant managing physician. "He has a unique understanding of the science of cancer, with an extensive background in microbiology and biochemistry, and a passion for walking alongside his patients—listening, guiding, and advocating for them throughout their treatment journey."

After receiving his medical degree from Ross University School of Medicine in Portsmouth, Dominica, Dr. Ezekwudo completed internal medicine residency training at Central Michigan University in Saginaw and a fellowship in hematology and medical oncology at the Oakland University William Beaumont School of Medicine in Royal Oak, Michigan, where he received several awards for scholarly activity. Dr. Ezekwudo pursued his medical training after earning a doctorate in pharmacology at Mercer University College of Pharmacy in Atlanta.

Previously, he served as program director of the hematology and oncology fellowship program for the Corewell Health William Beaumont University Hospital.

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

SOURCE Florida Cancer Specialists & Research Institute